AstraZeneca Stock News

Bloomberg Intelligence highlights 50 Companies to Watch for 2025, focusing on catalysts like leadership changes, M&A, and sector trends such as AI and EVs. Dogcatcher analysis identifies 13 dividend-paying stocks as 'safer,' with free cash flow yields exceeding dividend yields, including AVGO, KLAC, FOX, TPR, and WM. Top ten dividend focus stocks, including SLB, UPS, and WM, are projected to de...

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.

AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and efficient R&D investment, supporting steady share price appreciation and dividend growth. The company is fairly valued, possibly slightly undervalued, with a buy rating for long-term, lower-risk investors...

The UK's two big drugmakers came under the spotlight in Berenberg's latest review of the pharmaceuticals sector. AstraZeneca PLC (LSE:AZN) gets a clear thumbs-up with a 'buy' rating and price target of £142, implying around 24% upside from £114.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca's SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The...

AstraZeneca PLC (LSE:AZN) has reported positive results from a late-stage study of Saphnelo, its treatment for systemic lupus erythematosus (SLE), showing the drug was effective when given as a self-administered injection under the skin. The phase III TULIP-SC trial met its main goal at an interim analysis, demonstrating that patients receiving subcutaneous Saphnelo had a statistically signific...

AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).

AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in its home market.